Business Context and Reporting Period
This Form 6-K filing by Alcon, Inc. covers the month of October 2002. The report incorporates by reference a press release issued on October 18, 2002, announcing a significant regulatory milestone for the company's surgical division.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a product approval announcement rather than financial performance data.
Material Changes
The primary material event is the U.S. Food and Drug Administration (FDA) approval of Alcon's customized wavefront-guided laser eye surgery application. Alcon became the first company to receive FDA approval for customized LASIK surgery utilizing both a wavefront measurement device and an excimer laser.
Outlook, Risks, and Management Commentary
- Technology: The approved system integrates the LADARVision 4000 excimer laser and the LADARWave wavefront measuring device to treat high and low order aberrations unique to each patient.
- Management Commentary: Dr. Steven Brint noted the potential to improve visual acuity and quality of vision, particularly for low-contrast activities like night driving. Bill Barton, VP and General Manager of the Surgical Division, emphasized the industry anticipation for this technology.
- Forward-Looking Statements: The company cautions that actual results may differ due to general economic conditions, competitor technological advances, new product marketing challenges, and government regulation.
- Commercial Status: The LADARVision 4000 and other refractive products are commercially available in the United States and international markets.
Investor Verification Checklist
- Verify the commercial launch timeline and initial adoption rates of the LADARVision 4000 system following FDA approval.
- Monitor the status of ongoing clinical trials for myopic astigmatism, hyperopia, and other ocular irregularities.
- Assess competitive responses from other ophthalmic device manufacturers regarding wavefront-guided technology.
- Review subsequent quarterly reports for the financial impact of this new product line on the Surgical Division.